Sales & Marketing News | pharmaphorum

News

UK pharma industry delivers election ‘wish list’

The Association of the British Pharmaceutical Industry (ABPI) is calling on political parties contesting the general election to spell out their plans to nurture and drive growth in t

News

ALZpath licenses Alzheimer’s diagnosis tech to Roche

Diagnostics giant Roche is putting its weight behind a biomarker for Alzheimer’s disease developed by ALZpath.

News

FDA clears Ipsen’s primary biliary cholangitis drug

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (

News

Close-up view of an actinic keratosis lesion

FDA OKs wider use of Almirall’s actinic keratosis drug

With actinic keratosis (AK) diagnoses on the rise, there is some good news for patients, with the FDA approval of expanded use of Almirall’s topical therapy Klisyri.

News

Cycle Pharma makes $466m takeover bid for Vanda

UK group Cycle Pharma has made an unsolicited takeover bid to buy Vanda Pharma of the US, which is already fending off an overture from Future Pak.

News

Nestle bids to take control of Seres’ C diff drug Vowst

Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upg

UK pharma industry delivers election ‘wish list’

ALZpath licenses Alzheimer’s diagnosis tech to Roche

FDA clears Ipsen’s primary biliary cholangitis drug

FDA OKs wider use of Almirall’s actinic keratosis drug

Cycle Pharma makes $466m takeover bid for Vanda

Nestle bids to take control of Seres’ C diff drug Vowst

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks